Grant: Team Grant: Human Immunology Initiative: Research Teams - LOI
University of Manitoba
$20,000.00
Prediction and Prevention of Rheumatoid Arthritis in Indigenous North American Populations
FY 2018-19
Summary
Rheumatoid arthritis (RA) is a prevalent autoimmune disease that causes progressive damage to joints and internal organs. It is known that individuals destined to develop future RA have autoantibodies (Ab) in their blood that are detectable months to years before disease becomes clinically evident. Our previous studies have shown that RA is particularly common in Indigenous North American (INA) Populations, and that this is based on complex and unique interactions between genetic and environmental factors. Since 2005, we have systematically followed more than 750 unaffected family members of INA RA patients to determine their risk of developing future RA. To date, 20 individuals have developed RA, giving a transition rate of ~1% per year of followup. As shown in other studies, the detection of RA Abs, such as ACPA and RF, increased the risk of future RA. Importantly, our study showed that most Ab positive individuals do NOT develop RA. This compelled us to find better ways of predicting future RA that are based on understanding the immunological abnormalities involved in this preclinical stage, and how these abnormalities advance over time in some individuals and not others. Our ultimate aim is to find effective and safe approaches that will allow us to measurably reduce RA risk in predisposed individuals.
In consultation with INA People, and based on existing human and animal model data, we propose that a combination of dietary supplements: vitamin D, omega-3 PUFA, and curcumin, is deemed to have an appropriate balance of potential effectiveness and safety. As a first step, we showed that this combination reduces the onset of arthritis in a mouse model of RA. We now propose a clinical study in ACPA+ individuals to test the effects of this dietary supplement combination on a panel of predictive biomarkers that we are developing using state-of-the-art analytical platforms. This will also provide a template for future RA prevention studies that use other approaches.
Department
Program
Team Grant: Human Immunology Initiative: Research Teams - LOI
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
395679
Name
El-Gabalawy Hani S
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Human Immunology Initiative - Research Teams
Projecttitle
Prediction and Prevention of Rheumatoid Arthritis in Indigenous North American Populations
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$20,000
Cihrequipment2
$0
Programname2
Team Grant: Human Immunology Initiative: Research Teams - LOI
Keyworddelim
Knowledge Translation To Indigenous Communities; Prediction Model For Rheumatoid Arthritis (Ra); Reducing Risk Of Ra With Dietary Supplements
Abstract
Rheumatoid arthritis (RA) is a prevalent autoimmune disease that causes progressive damage to joints and internal organs. It is known that individuals destined to develop future RA have autoantibodies (Ab) in their blood that are detectable months to years before disease becomes clinically evident. Our previous studies have shown that RA is particularly common in Indigenous North American (INA) Populations, and that this is based on complex and unique interactions between genetic and environmental factors. Since 2005, we have systematically followed more than 750 unaffected family members of INA RA patients to determine their risk of developing future RA. To date, 20 individuals have developed RA, giving a transition rate of ~1% per year of followup. As shown in other studies, the detection of RA Abs, such as ACPA and RF, increased the risk of future RA. Importantly, our study showed that most Ab positive individuals do NOT develop RA. This compelled us to find better ways of predicting future RA that are based on understanding the immunological abnormalities involved in this preclinical stage, and how these abnormalities advance over time in some individuals and not others. Our ultimate aim is to find effective and safe approaches that will allow us to measurably reduce RA risk in predisposed individuals.
In consultation with INA People, and based on existing human and animal model data, we propose that a combination of dietary supplements: vitamin D, omega-3 PUFA, and curcumin, is deemed to have an appropriate balance of potential effectiveness and safety. As a first step, we showed that this combination reduces the onset of arthritis in a mouse model of RA. We now propose a clinical study in ACPA+ individuals to test the effects of this dietary supplement combination on a panel of predictive biomarkers that we are developing using state-of-the-art analytical platforms. This will also provide a template for future RA prevention studies that use other approaches.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
El-Gabalawy, Hani S; Mookherjee, Neeloffer; Peschken, Christine A; Wilkins, John A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $20,000~ $0~